# Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma

> **NCT00276055** · PHASE1 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 38 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Gemcitabine, Docetaxel and Bevacizumab

## Key facts

- **NCT ID:** NCT00276055
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276055, "Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00276055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*